Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no clinical content, eligibility criteria, results, or critical page data were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check15 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. This appears to be a metadata update and does not affect core content or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check30 days agoChange DetectedAdded: Show glossary option, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check37 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no page content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedAdded a Locations section listing Pennsylvania as the study site and removed the old Pennsylvania Locations entry. Updated page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check86 days agoChange DetectedThe page revision label updated from v3.3.1 to v3.3.2. The previous revision label v3.3.1 is removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.